France adopted the “Loi de financement de la sécurité sociale (LFSS) pour 2026,” which entered into force in January 2026. This reform introduces a strengthened regulatory framework for pharmaceutical rebates, clawback mechanisms, and pricing rules.

Marbls partners with pharmaceutical and medical device and diagnostic manufacturers to provide practical, innovative services that address complex pricing, contracting and commercial excellence needs — driving the path of critical drugs, devices, and diagnostics to market. We invest in the long-term success of our clients by investing in our employees. As a team with world-class experience and a client-first philosophy, we create long term relationships based on success, service and trust. Our approach is results driven, hands-on and flexible to address the unique internal and external dynamics impacting our clients.